If you're searching for the future of transportation, look up. Transportation startup Skyryse just completed an end-to-end autonomous helicopter flight, where the pilot never had to touch the controls.

"This is a really large step toward realizing a transportation system in the sky that can one day move us away from the cars and the crumbling infrastructure that is throughout our cities," explained Mark Groden, the company's founder and CEO.

While the helicopter, called Luna, isn't to be overlooked, it isn't the main attraction as far as Skyryse is concerned. That distinction belongs to the Skyryse Flight Stack technology, which the company hopes will revolutionize short-distance air travel. The sector is flooded right now, with as many as 130 companies looking for a piece of the pie, including big names like Uber involved. Skyryse isn't looking to beat them, but assist them.

"What we're focused on is building the technology that will lead to this transportation system," said Groden.

Reliable, widely-used short-distance air travel has seemed like something of a pipe dream until now, but Groden is quick to point out the first automated flight actually took place decades ago, when the Lockheed-1011 safely crossed the Atlantic. The idea of automated air travel isn't a new one, and the CEO believes it will expedite the process of making it a reality.

"The pragmatic approach we're taking, following existing paths that the FAA is already very keen to work with us on, will allow us to realize this in single-digit years, and far sooner than I think a lot of people expect," he said.

Share:
More In Business
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More